Skip to content
HowShorted

Intra-Cellular Therapies Inc. short interest in 2019

In 2019, Intra-Cellular Therapies Inc.'s disclosed short interest ran from 5.15% of shares outstanding on 15 Jan 2019 to 15.14% on 31 Dec 2019, a change of +9.99 percentage points. The year's high was 23.26% on 13 Dec 2019 and its low 5.15% on 15 Jan 2019, averaging 11.03% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.13 days on 15 Nov 2019. Full history: Intra-Cellular Therapies Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Intra-Cellular Therapies Inc. in 2019

2019 in figures

Start of year
5.15% (15 Jan 2019)
End of year
15.14% (31 Dec 2019)
Change
+9.99 pp
High
23.26% (13 Dec 2019)
Low
5.15% (15 Jan 2019)
Average
11.03%
Highest days to cover
16.13 (15 Nov 2019)
SEC filings marked
8

Every report in 2019

Intra-Cellular Therapies Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 20195.15%8.96
31 Jan 20195.30%7.46
15 Feb 20195.43%10.69
28 Feb 20195.43%7.8710-K filed, results (8-K)
15 Mar 20195.70%10.01
29 Mar 20195.68%9.82
15 Apr 20196.14%12.63
30 Apr 20196.24%10.99
15 May 20195.91%9.0210-Q filed, results (8-K)
31 May 20197.70%13.43
14 Jun 20198.50%9.81
28 Jun 20198.49%6.80
15 Jul 201912.83%3.26
31 Jul 201914.74%3.80
15 Aug 201912.83%9.1410-Q filed, results (8-K)
30 Aug 201911.42%12.70
13 Sep 201911.23%5.19
30 Sep 201916.13%7.66
15 Oct 201917.09%10.59
31 Oct 201916.92%16.09
15 Nov 201917.91%16.1310-Q filed, results (8-K)
29 Nov 201919.54%10.38
13 Dec 201923.26%10.37
31 Dec 201915.14%1.00

See also: Intra-Cellular Therapies Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.